Chronic Fatigue Syndrome.
Conditions
Interventions
Intervention 1: Treatment Group : Receives: 2 Piloshot capsules (500 mg each, produced by BSK Pharmaceutical Company) daily Dosage: 1 capsule in morning + 1 capsule in evening Durati
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of Chronic Fatigue Syndrome based on the Chronic Fatigue Syndrome Questionnaire Age above 18 years and below 65 years
Exclusion criteria
Exclusion criteria: Active medical conditions that could explain chronic fatigue (e.g., untreated hypothyroidism, sleep apnea, narcolepsy, drug side effects) Unresolved prior medical diagnoses (e.g., chronic hepatitis, malignancies) Current or history of psychiatric disorders (e.g., major depressive disorder with psychotic/melancholic features, bipolar disorder, schizophrenia, anxiety disorders, dementia, eating disorders) Use of medications that may interfere with study results or cannot be safely discontinued Pregnancy or lactation Non-compliance with study follow-up Tobacco use, alcohol consumption, or substance abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of chronic fatigue syndrome symptoms. Timepoint: Baseline (pre-intervention) - Week 4 post-treatment - Week 8 post-treatment - Week 12 post-treatment. Method of measurement: Standardized fatigue severity questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Vahidi
Zahedan University of Medical Sciences
Outcome results
None listed